XML 48 R33.htm IDEA: XBRL DOCUMENT v3.19.2
Equity (Tables)
 6 Months Ended
Jun. 30, 2019
Stockholders' Equity Note [Abstract]  
Summary of share-based compensation expense
Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows:
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
Cost of products sold
 
$
5

 
$
12

 
$
20

 
$
16

Research and development
 
33

 
35

 
105

 
107

Selling, general and administrative
 
49

 
38

 
151

 
153

Pre-tax compensation expense
 
87

 
85

 
276

 
276

Tax benefit
 
16

 
19

 
49

 
48

After-tax compensation expense
 
$
71

 
$
66

 
$
227

 
$
228
Summary of quarterly cash dividends
The following table summarizes quarterly cash dividends declared during 2019 and 2018:
2019
 
2018
Date Declared
 
Payment Date
 
Dividend Per Share
 
Date Declared
 
Payment Date
 
Dividend Per Share
06/20/19
 
08/15/19
 
$
1.07

 
11/02/18
 
02/15/19
 
$
1.07

02/21/19
 
05/15/19
 
$
1.07

 
09/07/18
 
11/15/18
 
$
0.96


 

 


 
06/14/18
 
08/15/18
 
$
0.96


 

 


 
02/15/18
 
05/15/18
 
$
0.96
Summary of changes in balances of each component of accumulated other comprehensive loss
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2018:
(in millions)
Foreign currency
translation adjustments
 
Net investment
hedging activities
 
Pension 
and post-
employment
benefits
 
Marketable
 security activities
 
Cash flow hedging
activities
 
Total
Balance as of December 31, 2017
$
(439
)
 
$
(203
)
 
$
(1,919
)
 
$
—

 
$
(166
)
 
$
(2,727
)
Other comprehensive income (loss) before reclassifications
(280
)
 
105

 
9

 
(6
)
 
110

 
(62
)
Net losses reclassified from accumulated other comprehensive loss
—

 
—

 
62

 
4

 
84

 
150

Net current-period other comprehensive income (loss)
(280
)
 
105

 
71

 
(2
)
 
194

 
88

Balance as of June 30, 2018
$
(719
)
 
$
(98
)
 
$
(1,848
)
 
$
(2
)
 
$
28

 
$
(2,639
)

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2019:
(in millions)
Foreign currency
translation adjustments
 
Net investment
hedging activities
 
Pension 
and post-
employment
benefits
 
Marketable
security activities
 
Cash flow hedging
activities
 
Total
Balance as of December 31, 2018
$
(830
)
 
$
(65
)
 
$
(1,722
)
 
$
(10
)
 
$
147

 
$
(2,480
)
Other comprehensive income (loss) before reclassifications
(32
)
 
35

 
2

 
10

 
7

 
22

Net losses (gains) reclassified from accumulated other comprehensive loss
—

 
(7
)
 
43

 
1

 
(70
)
 
(33
)
Net current-period other comprehensive income (loss)
(32
)
 
28

 
45

 
11

 
(63
)
 
(11
)
Balance as of June 30, 2019
$
(862
)
 
$
(37
)
 
$
(1,677
)
 
$
1

 
$
84

 
$
(2,491
)
Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss
The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions) (brackets denote gains)
2019
 
2018
 
2019
 
2018
Pension and post-employment benefits
 
 
 
 
 
 
 
Amortization of actuarial losses and other(a)
$
30

 
$
36

 
$
55

 
$
77

Tax benefit
(7
)
 
(7
)
 
(12
)
 
(15
)
Total reclassifications, net of tax
$
23

 
$
29

 
$
43

 
$
62

Cash flow hedging activities
 
 
 
 
 
 
 
Losses (gains) on designated cash flow hedges(b)
$
(37
)
 
$
46

 
$
(77
)
 
$
90

Tax expense (benefit)
2

 
(4
)
 
7

 
(6
)
Total reclassifications, net of tax
$
(35
)
 
$
42

 
$
(70
)
 
$
84

Net investment hedging activities
 
 
 
 
 
 
 
Gains on derivative amount excluded from effectiveness testing(c)
$
(9
)
 
$
—

 
$
(9
)
 
$
—

Tax expense
2

 
—

 
2

 
—

Total reclassifications, net of tax
$
(7
)
 
$
—

 
$
(7
)
 
$
—


(a) Amounts are included in the computation of net periodic benefit cost (see Note 10).
(b) Amounts are included in cost of products sold (see Note 9).
(c) Amounts are included in interest expense, net (see Note 9).